To update knowledge concerning the cause and consequences of the detrimental forms of innate immunity that inevitably occurs in peritransplant period tissue and cellular transplants. In addition, we review the information that a newly discovered, engraftment-promoting, and tolerance-inducing macrophage population is identified and characterized.
INTRODUCTION
Although there are center-to-center, organ-specific, recipient' and donor' age-related differences with respect to the preferred immunosuppressive protocol utilized, the immunosuppressive protocols utilized in the early transplant period are very intense and include high-dose anti-inflammatory corticosteroids than maintenance regimens. Why? The circumstances that attend harvest, preservation, and transplantation of organ and cellular transplants inevitably create an intense inflammatory state in the early posttransplant. This circumstance has impact upon the resilience of the transplant and upon the quantitative and qualitative aspects of the host antidonor adaptive immune response.
In renal transplantation, delayed graft function (DGF) and acute rejection are widely but not universally regarded as inter-related posttransplant complications that can contribute to impaired intermediate-term and long-term graft function and survival. We have tested the hypothesis that molecular evidence of intragraft expression of proinflammatory cytokines especially when linked with suboptimal expression of antiapoptotic genes and evidence of active T cell immunity presenting intraoperatively 10-15 min after revascularization and detected via PCR-based transcriptional profiling are linked to adverse posttransplant clinical outcomes such as DGF, acute rejection within 3 months following transplantation, and the quality of graft function 6 months and even 2 years posttransplantation [1, 2] . As a sidelight to this investigation, we determined that as compared with normal kidneys, every deceased donor renal transplant, even those without evidence of DGF, exhibits robust expression of proinflammatory cytokines. Taken together, these data suggest that detrimental intragraft inflammation is universal in the early posttransplant period and may point to the reason that potent anti-inflammatory agents such as high dose corticosteroids are required in the peritransplant period.
The fine molecular texture of inflammation within the microenvironment in which T cells recognize antigen directs the commitment of T cells into either tissue-protective (regulatory T cells; Tregs) or tissue-destructive helper T cell phenotypes. The presence of proinflammatory cytokines within this microenvironment polarizes antigen-activated CD4 þ T cells into tissue-destructive helper T cell (e.g., Th1, Th2, and Th17) phenotypes. An environment dominated by transforming growth factor beta leads to commitment to the CD4 þ regulatory T cells (Tregs) phenotype. In sharp contrast, the prominent appearance of certain proinflammatory cytokines such as interleukin-6 and interleukin-21, a member of the T cell growth factor family, favors differentiation into the Th17 phenotype and totally obviates the potential to direct naive T cells into Tregs, thereby leading to weak if not unopposed dominance of effector type Th1, Th2, and Th17 alloreactive T cells in the allograft response [3] . As noted above, interleukin-6 and other proinflammatory cytokines are abundantly expressed as a consequence of ischemia reperfusion injury in organ transplants [2] and in the disaster that leads to massive death of cell transplants before neoangiogenesis of the transplant occurs.
Danger molecules and ischemia reperfusion injury
Intracellular components of all normal cells are privileged in that they escape host recognition. Following ischemia reperfusion injury, prolonged hypoxia, and particularly with delayed reperfusion, these intracellular molecules, no longer contained within a membrane barrier, function as distress signals rapidly eliciting a potent innate immune response in a manner similar to pathogens. All tissue injuries release damage-associated molecular pattern molecules (DAMPs), a series of intracellular proteins released as a result of tissue injury. The most well described DAMPs include those from subcellular organelles and include HMGB1 and calreticulin, and from the cytoplasm including heat shock proteins, galectins, and S100A proteins. More recent data identify mitochondria, nucleotides including ATP as well as heme as powerful endogenous signaling molecules that emerge from the damaged cell and activate innate immunity. Each DAMP bears cognate receptor and these receptor molecules include RAGE, mincle, purinergic, and toll-like receptors (TLRs). Mitochondrial DAMPs (mtDAMPs) are important contributors to inflammation [4, 5] . Mitochondria are evolutionary endosymbionts derived from proteobacteria; thus, it is logical that mitochondria would bear molecular motifs that function as DAMPs. Indeed mitochondrial debriscontaining DAMPs enter the circulation after injury and contribute to systemic inflammation. In fact, mitochondrial DNA (mtDNA) circulates in critical illness in concentrations that predict systemic inflammation, sepsis, and clinical outcome [6] . In addition to mtDNA, mitochondria debris includes formyl peptides, mitochondrial DNA (mtDNA), and heme among other motifs. MT formyl peptides activate formyl peptide receptors and are potent chemoattractants; mtDNA activates immune cells via the direct and especially indirect effects of TLRs. Heme release upregulates heme oxygenases as a stress response gene to metabolize the prooxidant, heme. Adenosine triphosphate and adenosine are powerful signaling molecules that act on a battery of purinergic receptors that also contribute to modulation of an inflammatory response and alert the immune system of necrosis [7] . There is great direct tissue insult occurring during the harvest and transplantation of a solid organ. The requisite trauma
KEY POINTS
Ischemia reperfusion injury, graft hypoxia, and delayed neoangiogenesis create a virulent form of inflammation in the immediate posttransplant period.
This detrimental form of inflammation is likely the reason we are dependent upon corticosteroid treatment, albeit only modestly successful in curbing inflammation, in this period.
This detrimental inflammation is generated by liberation of immune-activating intracellular protein; proinflammatory cytokines heighten graft destroying antidonor immunity and is a huge hurdle to tolerance induction.
A newly discovered of potent tolerance promoting immunoregulatory tissue-resident macrophages has been discovered.
Manipulations that promote the longevity of this inherently fragile population promote transplant tolerance.
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followed by ischemia reperfusion injury without question results in the release of a tremendous payload of DAMPs that wreak havoc both locally in the transplanted organ, but in all likelihood contribute to systemic inflammatory responses in the recipient. Exposure of dendritic cells to DAMPs rapidly enhances their maturation and amplifies the T cell responses [8] . HMGB1 is required for the accumulation of T cells into tissues directed by macrophages and dendritic cells [9] . Mitochondrial debris released after tissue injury leads to activation of gd T cells, therein initiating a sterile inflammatory response that ultimately impacts the healing process [10] .
In short, the early posttransplant period is attended by a potent innate immune response created by the release of immune-stimulating and tissue-damaging intracellular DAMP molecules that amplify immune cell activation and expression of cytokines that seriously limit commitment of naive T cells to the Tregs phenotype and reciprocally foster potent tissue-destructive effector immunity. DAMPs also increase endothelial cell permeability and parenchymal cell expression of profibrotic tissue remodeling proteins that further contribute to chronic disease including transplant vascular stenosis [6] .
Interfering with DAMP-mediated immune events that otherwise lead to disease will prove challenging. There are a number of active efforts underway led by biotech and pharmaceutical companies. The characterization of antibodies against formyl peptides and mitochondria as well as medicinal chemistry efforts toward design of novel small molecule formyl peptide receptor inhibitors are in early preclinical development. Other approaches include inhibition of HMGB1 with ethyl pyruvate or sRAGE, antagonists of TLR4 and RAGE, and even the use of rasburicase to remove uric acid as a proinflammatory molecule. One of the more notable yet underappreciated DAMPs is heme, which is present in large amounts in hemoglobinpacked erythrocytes, yet a large pool exists in all cells in which heme serves as a critical moiety in the function of numerous enzyme complexes. Free heme is recognized by TLR4 and rapidly degraded by heme oxygenase into three bioactive products including the bile pigments and carbon monoxide that have been shown to modulate the inflammatory responses. Given the potentially large number of DAMPs contained within cells, many of which have yet to be identified, a successful approach to interfering with their activity will prove challenging and not without potential collateral damage. In short, the early posttransplant is attended by a potent innate immune response. This results in the release of immune stimulating and tissue damaging intracellular DAMP proteins and amplified expression of cytokines that seriously limit commitment of naive T cells to the Tregs phenotype and reciprocally foster potent tissue destructive effector immunity. That intracellular molecules activate the immune response has led to an explosion of research and the likely emergence of an entire new field of study with direct applicability to transplantation.
Peritransplant inflammation is dangerous
As noted above, in renal transplantation, DGF and acute rejection are linked, suggesting that the heightened inflammatory response that is causal for DGF is also linked to rejection. The issues arising from inflammation in the peritransplant period in the setting of islet transplant are even more detrimental as most islets die from a macrophage-rich inflammatory state within the peritransplant period. The losses are so profound that clinical application of islet transplantation has been slowed by the inability to routinely utilize islets from a single donor to restore euglycemia, even short-term, and by the unacceptably high 5-year failure rate even for islet transplants that function at 1 year posttransplantation [11] . As a result of nonimmunologic processes, many islets perish during harvest, purification, and shortly following transplantation [12, 13] . Moreover, the marked nonimmunologic loss of islets may render the recipient prone to beta cell exhaustion long-term [14] .
Alpha 1-antitrypsin (AAT), an acute-phase reactant serine protease inhibitor with anti-inflammatory, antileukocyte migratory, antithrombotic, complement inhibition, and antiapoptotic effects but without direct effects on isolated T cells [15] [16] [17] [18] , exerts cytoprotective effects upon islets in vitro [17, 19] . Short-term AAT treatment restores euglycemia and self-tolerance to islets in overtly type I diabetic, nonobese diabetic mice. We studied the impact of short-term AAT treatment upon the fate of marginal mass syngeneic islet transplants in highly reproducible syngeneic mouse and autologous nonhuman primate models. In the mouse model, primary nonfunction was noted in all recipients of untreated mice, but syngeneic islets transplants 90% of treated mice [20] . In the autologous monkey islet transplant model, frank diabetes was noted in each control by 6 months posttransplantation, but short-term AAT treatment insured long-term, apparently permanent graft survival in each recipient [3] . Using genome-wide arrays and systems biology analysis, AAT treatment produced potent inhibition of a powerful intragraft inflammatory process. AAT treatment also grossly inhibited graft infiltration by circulating macrophages. Studies are now in progress to determine whether AAT treatment can be used safely and effectively as an adjunct to several other regimens that tilt the allograft response toward tolerance in cynomolgus monkey allograft models.
Tissue resident anti-inflammatory macrophages
It is now evident that Tregs are not the only immunoregulatory cells that can inhibit rejection and promote tolerance. It is beyond the scope of this review to comment upon the role of regulatory B cells, mesenchymal-derived stem cells, and immunoregulatory dendritic cells and previously described conventional circulating immunoregulatory macrophages. Instead, we will briefly describe a subpopulation of tissue-resident macrophages that exert powerful immunosuppressive effects and promote long-term engraftment and tolerance of allogeneic mouse cardiac transplants [21 && ]. These tissue-resident macrophages unlike monocytederived circulating macrophages are Ly6C null and express CD169 and other cell surface siglec molecules. This Ly6C null, CD160 þ population is heterogeneous and not all tissue-resident macrophages are immunoregulatory. To our surprise, we found that the primary macrophage population present in hearts is a population that is Ly6C À , CD169 þ , F4/80 þ , and expresses other macrophage markers. This population also robustly expresses T cell immunoglobulin and mucin (TIM-4). TIM-4 and other TIM proteins possess a phosphatidylserinebinding pocket that commit these cells to bind to dead and dying cells, as phosphatidylserine is present on the surface of dead and dying cells.
The previously uncharacterized (TIM-4 hi ) subset of CD169 þ M2-like tissue-resident macrophages is a major subset of tissue-resident macrophages and is present in normal as well as transplanted hearts [21 && ]. Although tissue-resident macrophages have been regarded as sessile, these cells home to draining lymph nodes following oxidative stress and are therefore capable of delivering alloantigen to transplant draining lymph nodes. These cells exhibit an immunoregulatory and hypostimulatory phenotype as they express many of the immunoregulatory molecules produced by Tregs. This phenotype is maintained following migration to secondary lymphoid organs. As compared with conventional allogeneic Ly6C þ macrophages, the TIM-4hi subset of CD169þ M2-like tissue-resident macrophages favors (five-fold) preferential induction of antigen-stimulated Tregs in the mixed lymphocyte response [21 && ]. Yet these immunoregulatory macrophages are fragile and disappear from the transplant just before rejection occurs.
We learned that this subpopulation of tissueresident macrophages is also very fragile in vitro and highly susceptible to apoptosis in an oxidation stress model. In contrast, these Ly6C null, CD169þ tissueresident macrophages are resistant to oxidation stress-induced apoptosis in TIM-4 À/À mice. Compared with wild-type heart allografts, TIM-4 À/À heart allografts placed into untreated recipients survived over a month longer and were easily tolerized with suboptimal doses of sirolimus [21 && ]. Thus, M2-like TIM-4 hi , CD169 þ tissue-resident macrophages are immunoregulatory and promote engraftment of cardiac allografts, but their influence is diminished by TIM-4-dependent programmed cell death.
We conclude that a TIM-4 hi subset of Ly6C À CD169 þ tissue-resident macrophages: constitutes a major subset of Ly6C À tissue-resident macrophages; homes to draining lymph nodes following oxidative stress, a major site for T cell activation; exhibits an immunoregulatory and hypostimulatory phenotype that is maintained following migration to draining lymph nodes (dLNs); favors preferential induction of antigen-stimulated Tregs; is highly susceptible to apoptosis; and is rendered resistant to apoptosis via genetic ablation of TIM-4 expression. As a consequence, TIM-4 À/À heart allografts placed into untreated recipients survived much longer than wild-type hearts and survived indefinitely with the addition of a short, suboptimal rapamycin treatment regimen. Inflammation creates a milieu in which there is oxidative stress. Thus, TIM-4 hi CD169 þ tissue-resident macrophages are immunoregulatory and hypostimulatory, but their long-term influence is diminished by their susceptibility to programmed cell death in response to oxidative stress. We are now testing the hypothesis that anti-TIM-4 monoclonal antibodies able to protect the TIM-4 hi subset of CD169 þ M2-like tissue-resident macrophages from apoptosis will promote long-term engraftment and tolerance.
CONCLUSION
In this review, we have described the detrimental influence of proinflammatory tissue injury and cell death that occurs in the peritransplant period. This situations leads to dysfunction of organ allografts, tremendous loss of islet cell transplants and leads directly to heightened antidonor immunity. A major effort to modify and diminish this detrimental form of immunity seems justified. A new population of engraftment and tolerance promoting tissue-resident macrophages has been identified. This population is fragile and efforts to promote Innate immunity and the allograft response Otterbein et al.
their longevity lead to prolonged engraftment and high susceptibility to tolerance. A strategy to identify therapies that promote their longevity and translation to the clinic is outlined.
